文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

早产儿眼底检查中小剂量复方托吡卡胺滴眼液散瞳效果观察

[Clinical observation on the mydriatic effects of different doses of compound tropicamide eye drops during fundus examination of premature infants].
PubMed 文献 · Zhonghua Yan Ke Za Zhi · 2026-01-01

该研究为在郑州大学第一附属医院开展的非劣效性随机对照交叉试验,纳入72例拟行早产儿视网膜病变筛查的早产儿,比较45 μl与90 μl复方托吡卡胺滴眼液的散瞳效果与安全性。结果显示小剂量散瞳效果不劣于标准剂量,且安全性有一定优势。

要点

  • 早产儿眼底筛查中45 μl复方托吡卡胺散瞳效果不劣于90 μl。
  • 小剂量组检查困难率7%,标准剂量组3%,率差无统计学意义。
  • 小剂量组不良事件3次,标准剂量组11次。

核心结论

  • 早产儿眼底筛查中小剂量(45 μl)复方托吡卡胺滴眼液散瞳效果不劣于标准剂量(90 μl)。
  • 小剂量方案在安全性方面有一定优势。

研究设计与样本

  • 非劣效性随机对照交叉试验,纳入2024年10月至2025年6月郑州大学第一附属医院新生儿科住院拟行早产儿视网膜病变筛查的早产儿。
  • 共纳入72例,A组34例(1例第二次检查失访),B组38例(3例第二次检查失访)。
  • A组先后接受标准剂量(90 μl)和小剂量(45 μl),B组顺序相反。
  • 主要疗效指标为散瞳后60~75 min瞳孔直径和眼科医师评估的眼底检查难易程度。

主要发现

  • 散瞳后60~75 min,小剂量与标准剂量瞳孔直径差值为0.24 mm(95%CI:0.18~0.29),95%CI上限低于非劣效性界值。
  • 标准剂量检查困难率3%(95%CI:1%~11%),小剂量7%(95%CI:3%~16%),率差4%(95%CI:-1%~9%,P=0.087;Bonferroni校正后P=0.435)。
  • 小剂量组经皮氧饱和度低0.09%(95%CI:-0.32~0.15,P=0.470;校正后P=1.000),心率低0.34次/min(95%CI:-1.11~0.43,P=0.381;校正后P=1.000),差异均无统计学意义。
  • 小剂量组收缩压低0.45 mmHg(95%CI:-0.86~-0.05,P=0.028;校正后P=0.140),舒张压低0.65 mmHg(95%CI:-1.05~-0.25,P=0.001;校正后P=0.005),仅舒张压差异有统计学意义。
  • 标准剂量组不良事件11次,小剂量组3次。

关键数值与推荐

  • 非劣效性通过瞳孔直径差值的95%CI上限与非劣效性界值比较判定。
  • 检查困难率率差95%CI下限高于-5%。
  • 两组出生胎龄分别为(30.85±2.38)和(31.81±2.61)周,出生体重分别为(1 262.06±422.56)和(1 357.63±389.31)g,男性分别占35.29%(12例)和50.00%(19例)。

临床怎么用

  • 早产儿眼底筛查可考虑使用小剂量(45 μl)复方托吡卡胺滴眼液替代标准剂量(90 μl)进行散瞳。
  • 小剂量方案散瞳效果不劣于标准剂量,且不良事件发生次数较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy and safety of low-dose compound tropicamide eye drops for pupillary dilation in premature infants undergoing the fundus examination. Methods: A non-inferiority, randomized, controlled, crossover trial was conducted. Preterm infants hospitalized in the Department of Neonatology, the First Affiliated Hospital of Zhengzhou University scheduled for retinopathy of prematurity screening between October 2024 and June 2025 were enrolled. Participants were randomly assigned to group A or group B using simple randomization. Group A received standard-dose (90 μl) compound tropicamide eye drops in the first fundus examination, but low-dose (45 μl) drops in the second examination, whereas group B received the two doses in the reverse order. The primary efficacy outcomes were the pupil diameter measured 60 to 75 minutes after dilation and the difficulty of fundus examination as assessed by the ophthalmologist (classified as easy, difficult, or impossible). The difference in pupil diameter between the two groups and its 95% confidence interval (CI) were calculated and compared with the non-inferiority margin to determine non-inferiority. The safety was assessed based on changes in vital signs and adverse events. A linear mixed model and generalized estimating equations were used to compare differences between groups. Results: A total of 72 infants were enrolled. Group A comprised 34 infants, of whom one was lost to follow-up during the second examination; group B comprised 38 infants, of whom three were lost to follow-up during the second examination. In the two groups, the gestational ages at birth were (30.85±2.38) and (31.81±2.61) weeks, the birth weights were (1 262.06±422.56) and (1 357.63±389.31) g, and male infants accounted for 35.29% (12 cases) and 50.00% (19 cases), respectively. No statistically significant differences were observed in demographic characteristics or clinical complications between the two groups (all P>0.05). At 60 to 75 minutes after dilation, the difference in pupil diameter between the low-dose and standard-dose regimens was 0.24 mm (95% CI: 0.18 to 0.29), with the upper limit of the 95% CI falling below the pre-specified non-inferiority margin. The rate of examination difficulty was 3% (95% CI: 1% to 11%) after standard-dose administration and 7% (95% CI: 3% to 16%) after low-dose administration, with a rate difference of 4% (95% CI: -1% to 9%, P=0.087; after Bonferroni correction, P=0.435). The lower limit of the 95% CI was above -5%. After low-dose administration, the oxygen saturation by pulse oximetry was 0.09% lower (95% CI: -0.32 to 0.15, P=0.470; after Bonferroni correction, P=1.000), and the heart rate was 0.34 beats/min lower (95% CI: -1.11 to 0.43, P=0.381; after Bonferroni correction, P=1.000), compared with standard-dose administration, with no statistically significant differences. The systolic blood pressure was 0.45 mmHg (1 mmHg=0.133kPa)lower (95% CI: -0.86 to -0.05, P=0.028; after Bonferroni correction, P=0.140), and the diastolic blood pressure was 0.65 mmHg lower (95% CI: -1.05 to -0.25, P=0.001; after Bonferroni correction, P=0.005) after low-dose administration compared with standard-dose administration, with only the difference in diastolic blood pressure reaching statistical significance. Adverse events occurred 11 times after standard-dose administration and 3 times after low-dose administration. Conclusion: For fundus screening in preterm infants, low-dose (45 μl) compound tropicamide eye drops are non-inferior to the standard dose (90 μl) in terms of mydriatic efficacy, while offering advantages in safety profile. 目的: 探讨小剂量复方托吡卡胺滴眼液在早产儿眼底检查中散瞳的有效性和安全性。 方法: 非劣效性随机对照交叉试验。纳入2024年10月至2025年6月在郑州大学第一附属医院新生儿科住院拟行早产儿视网膜病变筛查的受试者。简单随机化分为A、B两组,A组先后接受标准剂量(90 μl)和小剂量(45 μl)复方托吡卡胺滴眼液,B组则相反。以散瞳后60~75 min测量的瞳孔直径和眼科医师眼底检查的难易程度(容易、困难、无法检查)评价散瞳效果,计算使用不同剂量散瞳滴眼液受试者的瞳孔直径差值及其95%置信区间(95%CI),与非劣效性界值对比,用于评估非劣效性;以生命体征变化情况和不良反应发生情况评价安全性。采用线性混合模型和广义估计方差比较组间差异。 结果: 共纳入72例受试者。A组共34例,1例再次检查时失访;B组共38例,3例再次检查时失访。两组受试者的出生胎龄分别为(30.85±2.38)和(31.81±2.61)周,出生体重分别为(1 262.06±422.56)和(1 357.63±389.31)g,男性分别为12例(35.29%)和19例(50.00%);两组受试者人口统计学资料和临床并发症差异均无统计学意义(均P>0.05)。散瞳后60~75 min,使用不同剂量散瞳滴眼液的瞳孔直径差值为0.24 mm(95%CI:0.18~0.29),95%CI的最大值<非劣性界值。使用标准剂量散瞳滴眼液后检查困难率为3%(95%CI:1%~11%),使用小剂量散瞳滴眼液后为7%(95%CI:3%~16%),两组率差为 4%(95%CI:-1%~9%,P=0.087,Bonferroni校正后P=0.435),95%置信区间下限高于-5%。使用小剂量散瞳滴眼液后,经皮氧饱和度比标准剂量低0.09%(95%CI:-0.32~0.15,P=0.470,Bonferroni校正后P=1.000),心率比标准剂量低0.34次/min(95%CI:-1.11~0.43,P=0.381,Bonferroni校正后P=1.000),差异均无统计学意义。使用小剂量散瞳滴眼液后,收缩压比标准剂量低0.45 mmHg(95%CI:-0.86~-0.05,P=0.028,Bonferroni校正后P=0.140),舒张压比标准剂量低0.65 mmHg(95%CI:-1.05~-0.25,P=0.001,Bonferroni校正后P=0.005;1 mmHg=0.133kPa),仅舒张压差值有统计学意义。使用标准剂量散瞳滴眼液后,发生不良事件11次,使用小剂量散瞳滴眼液后,发生3次。 结论: 早产儿眼底筛查中小剂量(45 μl)复方托吡卡胺滴眼液散瞳效果不劣于标准剂量(90 μl),且在安全性方面有一定优势。.

来源:Zhonghua Yan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Li GP, Xu YL, Hao QF, et al. [Clinical observation on the mydriatic effects of different doses of compound tropicamide eye drops during fundus examination of premature infants]. Zhonghua Yan Ke Za Zhi. 2026. PMID: 42103666. doi:10.3760/cma.j.cn112142-20250915-00381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。